Access the presentations, panel discussions and proceedings from the 2023 ATTR Patient Summit here.

Hello, my name is Anne Marie Carr, Founder and CEO of Transthyretin Amyloidosis Canada (TAC), formerly Hereditary Amyloidosis Canada. Our mission at TAC is to serve those with transthyretin amyloidosis in Canada. I live with Hereditary Transthyretin Amyloidosis (hATTR). I currently live in Hagersville, Ontario with Mervyn, my husband. I have a son and am a grandmother to lovely Abigail.

Like many of you, the road to diagnosis has been long and confusing. When my first symptoms appeared such as breathing problems, they were considered asthma caused by environmental factors. My weight loss and chronic diarrhea were attributed to viruses that were circulating at the time. I remember that tingling sensation in my fingertips, and I had trouble opening a bottle of water or buttoning my clothes. I was finally diagnosed with hATTR in September 2015.

To all of you who suffer from ATTR, please tell yourself that I know that there are days when you feel alone, and the symptoms are simply intolerable.

Know, however, that YOU ARE NOT ALONE.

To sign up for the latest updates, including Canadian-focused news and information about ATTR please click here.

Latest Updates

Onpattro™ (patisiran) is now approved in Canada

Alnylam Pharmaceuticals, Inc. Announce Health Canada’s Approval of Onpattro™ (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. To learn more, please...

read more

Access to Treatment in Québec – Have Your Say

L’INESSS in Québec is evaluating inotersen (Tegsedi – Akcea Therapeutics Canada) a treatment for adults with hATTR amyloidosis polyneuropathy. L’INESSS does this evaluation to determine whether to recommend the drug for reimbursement by the Québec government....

read more

HAC Needs YOU! Tegsedi Survey Closes March 1

If you are a person living with hATTR amyloidosis, or a caregiver for a person living with hATTR amyloidosis, we would greatly appreciate it if you could take 15 minutes to complete a questionnaire regarding Tegsedi, a medication recently approved by Health Canada....

read more

Mark Your Calendars! Rare Disease Day is February 28, 2019

Rare Disease Day is held on the last day of February each year to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To learn more, or to get involved, please visit their...

read more

Like us on Facebook

Visit our Facebook page here.

Like us on Twitter

Visit our Twitter page here.

Find other ways to connect

Visit our Contact Us page here.

Sign up to Stay in Touch!

Get important updates, including Canadian-focused news and information about ATTR, delivered to your inbox.

11 + 7 =

*By submitting this form, you are consenting to receive emails from Hereditary Amyloidosis Canada. You can revoke your consent to receive emails at any time by using the unsubscribe link, found at the bottom of every email.